Attenuating characteristics of DEN-2 PDK53 in flavivirus-naïve peripheral blood mononuclear cells

Vaccine

Volumn 25, Issue 19, 2007, Pages 3896-3905

  Rabablert, Jundee ^b,c   Wasi, Chantapong ^c   Kinney, Richard ^d   Kasisith, Jitra ^a   Pitidhammabhorn, Dhanesh ^a   Ubol, Sukathida ^a  

^a Mahidol University   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

cDNA array analysis; Dengue virus; Vaccine development

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENGUE VIRUS; DENGUE VIRUS 2 PDK53; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINE PRODUCTION; VIRUS ATTENUATION; VIRUS STRAIN; VIRUS VIRULENCE;

APOPTOSIS; CELLS, CULTURED; CYTOKINES; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 34247203627     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.096     Document Type: Article

References (53)

1. Rico-Hesse R., Harrison L.M., Salas R.A., Tovar D., Nisalak A., Ramos C., et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 230 (1997) 244-251
2. Leitmeyer K.C., Vaughn D.W., Watts D.M., Salas R., Chacon I.V., Ramos C., et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 73 (1999) 4738-4747
3. Vaughn D.W., Green S., Kalayanarooj S., Innis B.L., Nimmannitya S., Suntayakorn S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181 (2000) 2-9
4. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60 (2003) 421-467
5. Chen Y.C., and Wang S.Y. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol 76 (2002) 9877-9887
6. King C.A., Anderson R., and Marshall J.S. Dengue virus selectively induces human mast cell chemokine production. J Virol 76 (2002) 8408-8416
7. Lin Y.W., Wang K.J., Lei H.Y., Lin Y.S., Yeh T.M., Liu H.S., et al. Virus replication and cytokine production in dengue virus-infected human B Lymphocytes. J Virol 76 (2002) 12242-12249
8. Lin C.F., Chiu S.C., Hsiao Y.L., Wan S.W., Lei H.Y., Shiau A.L., et al. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus nonstructural protein 1. J Immunol 174 (2005) 395-403
9. Palmer D.R., Sun P., Celluzzi C., Bisbing J., Pang S., Sun W., et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 79 (2005) 2432-2439
10. Wu S.J., Grouard-Vogel G., Sun W., Mascola J.R., Brachtel E., Putvatana R., et al. Human Skin Langerhans cells are targets of dengue virus infection. Nat Med 6 (2000) 816-820
11. Libraty D.H., Pichayangkul S., Ajariyakhajorn C., Endy T.P., and Ennis F.A. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 75 (2001) 3501-3508
12. Suharti C., van Gorp E.C., Dolmans W.M., Setiati T.E., Hack C.E., Djokomoeljanto R., et al. Cytokine patterns during dengue shock syndrome. Eu Cytokine Netw 4 (2003) 172-177
13. Anderson R., Wang S., Osiowy C., and Issekutz A.C. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 71 (1997) 4226-4232
14. + cytotoxic T lymphocyte clones. J Virol 73 (1999) 3623-3629
15. Chang D.M., and Shaio M.F. Production of interleukin-1 (IL-1) and IL-1 inhibitor by human monocytes exposed to dengue virus. J Infect Dis 170 (1994) 811-817
16. Green S., Vaughn D.W., Kalayanarooj S., Nimmannitya S., Suntayakorn S., Nisalak A., et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179 (1999) 755-762
17. Lei H.Y., Yeh T.M., Liu H.S., Lin Y.S., Chen S.H., and Liu C.C. Immunopathogenesis of dengue virus infection. J Biomed Sci 8 (2001) 377-388
18. Chaturvedi U.C., Agarwal R., Elbishbishi E.A., and Mustafa A.S. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 28 (2000) 183-188
19. Rothman A.L. Immunology and immunopathogenesis of dengue diseases. Adv Virus Res 60 (2003) 397-419
20. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 (2002) 100-103
21. Halstead S.B., and Simasthien P. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J Biol Med 42 (1970) 276-292
22. Kinney R.M., Butrapet S., Chang G.J., Tsuchiya K.R., Roehrig J.T., Bhamarapravati N., et al. Construction of infectious cDNA clones for Dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK 53. Virology 230 (1997) 300-308
23. Butrapet S., Huang C.Y.H., Pierro D.J., Bhamarapravati N., Gubler D.J., and Kinney R.M. Attenuation markers of a candidate dengue type 2 vaccine virus, strain16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J Virol 74 (2000) 3011-3019
24. Yoksan S., Bhamarapravati N., and Halstead S.B. Dengue virus vaccine development: study on biological markers of uncloned dengue 1-4 viruses serially passaged in primary kidney cells. In: George T.D., Kay B.H., and Blok J. (Eds). Arbovirus Research in Australia, Proceeding of the 4th Symposium. CRIRO and Queensland Institute of Medical Research. Brisbane, Australia (1986) 35-38
25. Bhamarapravati N., Yoksan S., Chayaniyotin T., Angsubphakorn S., and Bunyaratavej A. Immunization with a live attenuated dengue 2 virus candidate vaccine (16681-PDK53): clinical immunological and biological responses in adult volunteers. Bull WHO 65 (1987) 189-195
26. Dharakul T., Kurane I., Bhamarapravati N., Yoksan S., Vaughn D.W., Hoke C.H., et al. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J Infect Dis 170 (1994) 27-33
27. Rabablert J., Dharakul T., Yoksan S., and Bhamarapravati N. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines. Asian Pac J Allergy Immunol 18 (2000) 227-235
28. Vaughn D.W., Hoke Jr. C.H., Yoksan S., LaChance R., Innis B.L., Rice R.M., et al. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine 14 (1996) 329-336
29. Lum L.C.S., Lam S.K., Choy Y.S., George R., and Harum F. Dengue encephalitis-a true entity. Am J Trop Med Hyg 54 (1996) 256-259
30. Pryor M.J., Carr J.M., Hocking H., Davidson A.D., Li P., and Wright P.J. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 65 (2001) 427-434
31. Huang C.Y.-H., Butrapet S., Pierro D.J., Chang G.J., Hunt A.R., Bhamarapravati N., et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 74 (2000) 3020-3028
32. Butrapet S., Rabablert J., Angsubhakorn S., Wiriyarat W., Huang C., Kinney R., et al. Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys. Southeast Asain J Trop Med Public Health 33 (2001) 589-599
33. Pitidhammabhorn D., Kantachuvesiri S., Totemchokchyakarn K., Kitiyanant Y., and Ubol S. Partial construction of apoptotic pathway in PBMC obtained from active SLE patients and the significance of plasma TNF-alpha on this pathway. Clin Rheumatol 25 (2006) 705-714
34. Liew K.J.L., Chow V.T.K., Microarray, and real-time. RT-PCR analyses of a novel set of differentially expressed human genes in ECV304 endothelial-like cells infected with dengue virus type 2. J Virol Methods 131 (2006) 47-57
35. Warke R.V., Xhaja K., Martin K.J., Fournier M.F., Shaw S.K., Brizuela N., et al. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J Virol 77 (2003) 11822-11832
36. Huang C.Y.-H., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., and Kinney R.M. Dengue PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 77 (2003) 11436-11447
37. Huang C.Y.-H., Silengo S.J., Whiteman M.C., and Kinney R.M. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus. J Virol 79 (2005) 7300-7310
38. Duarte dos Santos C.N., Frenkiel M.P., Courageot M.P., Rocha C.F., Vazeille-Falcoz M.C., Wien M.W., et al. Determinants in the envelope E protein and viral RNA helicase NS3 that influence the induction of apoptosis in response to infection with dengue type 1 virus. Virology 274 (2000) 292-308
39. Rulli N.E., Suhrbier A., Hueston L., Heise M.T., Tupanceska D., Zaid A., et al. Ross River virus: molecular and cellular aspects of disease pathogenesis. Pharmacol Ther 107 (2005) 329-342
40. Spain-Santana T.A., Marglin S., Ennis F.A., and Rothman A.L. MIP-1α and MIP-1β induction by dengue virus. J Med Virol 65 (2001) 324-330
41. Raghupathy R., Chaturvedi U.C., Al-Sayer H., Elbishbishi E.A., Agarwal R., Nagar R., et al. Elevated levels of IL-8 in dengue hemorrhagic fever. J Med Virol 56 (1998) 280-285
42. Talavera D., Castillo A.M., Dominguez M.C., Gutierrez A.E., and Meza I. IL-8 release tight junction and cytoskeleton dynamic reorganization conductive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol 85 (2004) 1801-1813
43. Medin C.L., Fitzgerald K.A., and Rothman A.L. Dengue virus nonstructural protein NS5 induces interleukin-8 transcription and secretion. J Virol 79 (2005) 11053-11061
44. Schall T.J., Bacon K., Toy K.J., and Goeddel D.V. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347 (1990) 669-671
45. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
46. Gale L.M., and McColl S.R. Chemokines: extracellular messengers for all occasions?. Bioessays 21 (1999) 17-28
47. Navarro-Sanchez E., Despres P., and Cedillo-Barron L. Innate immune responses to dengue virus. Arch Med Res 36 (2005) 425-435
48. Bhamarapravati N., and Yoksan S. Study of bivalent dengue vaccine in volunteers. Lancet 1 (1989) 1077
49. Bhamarapravati N., and Yoksan S. Live attenuated tetravalent dengue vaccine. Vaccine 18 Suppl. 2 (2000) 44-47
50. Kanesa-thasan N., Sun W., Kin-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19 (2001) 3179-3188
51. Rothman A.L., Kanesa-thasan N., West K., Janus J., Saluzzo J.F., and Ennis F.A. Induction of T lymphocyte responses to dengue virus by a candidate tetravalent live attenuated dengue virus vaccine. Vaccine 19 (2001) 4694-4699
52. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 (2002) 264-272
53. Bhamarapravati N., and Yoksan S. Live attenuated tetravalent dengue vaccine. In: Gubler D.J., and Kuno G. (Eds). Dengue and dengue hemorrhagic fever (1997), CAB International, New York, NY 367-377